Koroner Arter Lezyonlarının Tedavisinde Everolimus Salınımlı Koroner Stent Sisteminin (Xıence V) Etkinlik ve Güvenirliğinin Değerlendirilmesi

Abstract

Drug eluting stents have become an important component in percutaneous treatment of patients with symptomatic coronary artery disease. The population in the previous drug eluting stent studies has very risk profile and therefore not reflects real-world information. Moreover there are limited data to evaluate risk factors and predictors of intended outcomes. In this study, everolimus eluting stent (XIENCE V) implantations and follow up results in patients with coronary artery disease were evaluated. 833 patients who underwent everolimus eluting stent deployment for coronary artery lesions in Hacettepe University Faculty of Medicine Department of Cardiology between 1 January 2008 and 31 August 2013 included. Baseline demographic, clinic and angiographic data, procedure related complications and outcomes during follow up were studied. As primary endpoints all-cause mortality was %1,3 and target lesion failure was %2,2. As secondary outcomes, cardiac death, target leson revascolarization, target vessel revascularization, myocardial infarction, stent thrombosis and major adverse cardiovascular events were seen %0,84, %0,8, %2,2, %0,6, %0,24 and %5,6, respectively. For all outcomes, premature discontinuation of dual antiplatelet therapy was a strong predictor. Bİfurcation lesion and presentation with acute coronary syndrome were also observed as high risk critertia. Despite heterogeneity and high risk profile of our patients, procedural related complications and primary and secondary outcomes were very low with high clinical device and procedure success. These results demonstrate effectiveness and safety of the XIENCE V everolimus eluting stent in a highly complex, real world patient population.